Loading...
XRTX logo

XORTX Therapeutics Inc.NasdaqCM:XRTX Stock Report

Market Cap US$4.0m
Share Price
US$2.59
My Fair Value
n/a
1Y-43.7%
7D5.3%
Portfolio Value
​
View

XORTX Therapeutics Inc.

NasdaqCM:XRTX Stock Report

Market Cap: US$4.0m

XORTX Therapeutics (XRTX) Stock Overview

A late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. More details

XRTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($4M)

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)


XRTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

XORTX Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for XORTX Therapeutics
Historical stock prices
Current Share PriceCA$2.59
52 Week HighCA$7.05
52 Week LowCA$1.73
Beta0.22
1 Month Change14.10%
3 Month Change19.41%
1 Year Change-43.70%
3 Year Change-92.89%
5 Year Change-96.50%
Change since IPO-96.58%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 19

XORTX completes positive pre-phase 3 meeting with the FDA

XORTX Therapeutics (NASDAQ:XRTX) said it had completed the previously announced Type B Pre-phase 3 meeting with the U.S. Food and Drug Administration for XRx-008 program for the treatment of autosomal dominant polycystic kidney disease. Ahead of the meeting with the FDA, the Pre-Phase 3 Briefing Package provided an up-to-date summary of the work completed for the XRx-008 program, including updates regarding chemistry, manufacturing, pharmacology, toxicology, clinical results to date, and regulatory and clinical plans. The company said the FDA reviewed the package of data and responded with minimal comments on the work accomplished to date and focused their feedback on XORTX clinical planning. The FDA's focus of the meeting was on optimizing trial design. "A particularly valuable aspect of FDA advice was an emphasis on how the Company might gain market approval with a single phase 3 registration trial to demonstrate efficacy and safety," the company added. XORT has risen 1.5% before the bell.
Seeking Alpha • Aug 22

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

Xortx Therapeutics (NASDAQ:XRTX) said its proprietary formulation of oxypurinol showed a substantial increase in oral bioavailability provided with food compared to the fasted state in a pharmacokinetics bridging study, dubbed XRX-OXY-101, Part 2. The company added that the trial also showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events related to oral administration of oxypurinol. XRX-OXY-101 bridging pharmacokinetic study is designed with four important objectives, the company noted in an Aug. 22 press release. "Successful completion of Part 1 and now part 2 of the XRX-OXY-101 study provides key data and knowledge for selecting the clinical dose and formulation for future oral dosing for our planned phase 3 registration trial in ADPKD," said Xortx CEO Allen Davidoff. The company's planned phase 3 trial in autosomal dominant polycystic kidney disease (ADPKD) expects to begin patient dosing in H1 2023. XRTX +40.40% to $2.12 premarket Aug. 22
Seeking Alpha • Jul 13

XORTX jumps over 100% after early encouraging data for rare disease therapy

Nano-cap pharma XORTX Therapeutics (NASDAQ:XRTX) surged ~103% on above average volume in the pre-market Wednesday after the company announced encouraging results for its oxypurinol formulation from a pharmacokinetics bridging study. The trial XRX-OXY-101 was the Part 1 of the three-part pharmacokinetics bridging study conducted ahead of a Phase 3 registration trial in autosomal dominant polycystic kidney disease (“ADPKD”), a rare disease that affects more than 10M globally. According to topline data, two versions of XORTX’s (XRTX) oxypurinol formulation was found to have a substantial increase in oral bioavailability compared to a control, the company said. In addition, the oral administration of oxypurinol showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events, XORTX (XRTX) added. Last week, the company requested a type B Pre-Phase 3 meeting with the FDA, in connection with its clinical development of an ADPKD therapy.

Shareholder Returns

XRTXUS PharmaceuticalsUS Market
7D5.3%1.4%-0.3%
1Y-43.7%34.5%24.1%

Return vs Industry: XRTX underperformed the US Pharmaceuticals industry which returned 34.5% over the past year.

Return vs Market: XRTX underperformed the US Market which returned 24.1% over the past year.

Price Volatility

Is XRTX's price volatile compared to industry and market?
XRTX volatility
XRTX Average Weekly Movement19.2%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: XRTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: XRTX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aAllen Davidoffwww.xortx.com

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

XORTX Therapeutics Inc. Fundamentals Summary

How do XORTX Therapeutics's earnings and revenue compare to its market cap?
XRTX fundamental statistics
Market capUS$3.98m
Earnings (TTM)-US$2.77m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.4x
P/E Ratio

Is XRTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XRTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$2.77m
Earnings-US$2.77m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.79
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did XRTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 18:20
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

XORTX Therapeutics Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners